Protokoly_diagnostiki_i_lechenia_zabolevany

<

: 03-035

"$ &: "

: 6!

& ! : & " . !- .

) : + - 3 % .% " "$ 5 %, " ,.

% .

" & :

" & & :

1.&

2.&

3.&

4.7

$ . @ 3 & " 3 . ? # 3 " .

@ " ". H " " , " , " & "$.

" & :

1.* 200 , 500

2.*B 200 , 400

3._ 500

4.*7 250 , 500

5.*/ 250 , 500

6.V 300 /2 ,

" & & :

/ , & :

1.Prodigy Knowledge. Prodigy Guidance-Sore Throat Acute. 2004.

2.Institute For Clinical System Improvement. Health Care Guideline. Acute Pharyngitis. May 2005.

3.EBM Guideline. Sore Throat and Tonsillitis. 2004.

4.National Guideline Clearinghouse. Guideline. Sore Throat and Tonsillitis. December 2005.

5.National Guideline Clearinghouse. Guideline. Acute Pharyngitis. December 2005.

6.Scottish Intercollegiate Guidelines Network. National Clinical Guideline. Management of Sore Throat and Indications for Tonsillectomy. January 1999.

7.Alberta Medical Association. Guideline. The Diagnosis and Treatment of Acute Pharyngitis. November 2001.

8.American Society of Infection Diseases. A Practice Guideline. Diagnosis and Management of Group A Streptococcal Pharyngitis.1997.

9.University of Michigan Health System. Guidelines for Clinical Care. Pharyngitis. December 2000.

10.Advisory Committee. Guidelines & Protocols. Diagnosis and Management of Sore Throat. 2003.

11. American Society of Infection Diseases. Practice Guidelines for the Diagnosis and Management of Group A Streptococcal Pharyngitis.2002.

12.Paradise JL, Bluestone CD, Bachman RZ, et al. Efficacy of tonsillectomy for recurrent throat infection in severely affected

13.children. N Engl J Med 1984; 310:674-683

14.Paradise JL, Bluestone CD, Rogers KD, et al. Comparative efficacy of tonsillectomy for recurrent throat infection in more versus less severely affected children [abstract]. Pediatric Res 1992; 31: 126A.

* – , # (% % ) .

" & " FEV1 PEF ( mid-expiratory flow at 50% of forced vital capacity, MEF50) ;

" & % FEV1 ( V[ ) PEF ;

& " & & ;

, & , 3 #

& , ;

>;

2." ( , , , $, , , & , 3 & $, ,

3 , " , 3 ).

2.# (6 );

3.;

4.B ;

5.& ;

6.! " ( ) $# ".

" & & :

1.;

2.< ;

3.< ;

4.&$ .

+ :

' 1-4

K 1 $#

B $# 2 - K 2

@ & 200-400 / & BDP BUD 100-200 / & FP

– & & % *

H 2-4 & .

K 4 & & ' 5-15

K 1 $#

B $# 2 * K 2

@ & * 200-400 / & BDP BUD 100-200 / & FP – & & %

( * % & & )

K 3 &

1. 2 &

2. & 2 & 3. $ – % & $

4.& 3 2 & & , " &400 / & BDP BUD 200 / & FP ( & 3 % & )

5.$ 2 & – &$. & SR ** . 100

K 4 &

1." & 600-800 / & BDP BUD 300-400 / & FP

2.% & &$ $

& "

K 5 % &

1.&

2.% &

3.& *

8

% " &$# % & .

L & " , " , % , % &, & " *.

@ & & $ $$ % % & " # " .

" & :

1. ** ! & / 5 .; 0,5 /10 V ;

3.**< 200 ;

4.**_ $ 50 1 120;

5.** ! 25 / , 3 & ;

6.**; 300 ./ 100 ,200 ,300 ; 350 ;

7.* 1 , 5 ;

8.*B 100 3 &;

9.& (* 1 , 5 ; * 50,0).

" & & :

1.< 50 1 . 200 ;

2.*; 2,5-5 .;

3.7 10 .;

4.? 10 .

,- ! – :

% " (status astmaticus, &, 3 &).

/ , & :

1.PRODIGY Guidance – Asthma; Last revised in November 2004 www.prodigy.nhs.uk/guidance.asp?gt=Asthma

2.EBM Guidelines, 12.1.2005

3.Best practice evidence based guideline, management of asthma in children aged 1-15 years, 2005, paediatric society of New Zealand, www.paediatrics.org.nz

4.SIGN and BTS, 2004

5.Global Strategy for Asthma Management and Prevention, NIH Publication No 02-3659 Issued

January, 1995 (updated 2002) Management Segment (Chapter 7): Updated 2004 from the 2003 document. The GINA reports are available on www.ginasthma.org.

6.Asthma and other wheezing disorders in children Search date October 2004, Clinical Evidence, BMJ

7.Diagnosis and treatment of childhood asthma, EBM Guidelines, 12.1.2005

* – , # (% % ) ** - " & , "$ &

7

:18-159

"$ &: "

: 6!

& ! :

1."

2.%

' & & : 10-14

(: '01 ' '01.9 ' %

) : 7 –%&$ % " .

$ :

1.: - " ;

- " ( , , , " ; , );

2.% : , % , % ;

3."$: - ;

-( % , " ,

" ).

*

1." - & $# ;

2." & " & , # $ & ;

3." , %.

:

1.& $# ;

2.;

3. & ;

4.& % ;

5.% .

" & :

+ :

1)– % ( 1% ) , & &

2) % – % , & & ,( & 38,5 ! ) " *: 3 – 10 / , 3 – 1

– 60-120 , 1 – 5 – 120-250 , 6 – 12 – 250-500 , 12 ( & 60 ) – 500 . 7 .

3)& & % 200-800 / ( " ) -4 .

" & :

1.* 300-500 , .;

2.* 1% 10 , 20 .

" & & :

1.? 200 , 800 ; 5% &-2,0.

,- ! – :

1)% , " , ;

2)% :

-" : $# , 3 , , , " , , .

-" : , , , , ,

.

/ , & :

1.PRODIGY Guidance – Chickenpox Last revised in November 2004

2." , & : . ./ . M.J. K " , B.+. @ , '.B. , .6. G . – 2- ., . – 6.: 7 ;? – 6>@, 2002. – 1248 .: .

3.@ & . >% " . . < # !.>., 6 , 6-! , 2003 ., 2, " & 1, . 522-528.

4.Chickenpox EBM Guidelines 02.08.2001

* – , # (% % )

; !

: 18-148

"$ &: "

: 6!

& ! :

1. : , , % ;

2.! " " , ;

3., , " ".

7 . ' " " "$ Campylobacter, Salmonella, Shigella, Esherichia coli, Yersinia, , . < "

" " & .

3

$ :

1.! ;

2.B .

* :

1.& " , ;

2.-" % ;

3.;

4.;

5., .

:

1.3 ;

2.( );

3.% ( , 3 );

4.;

5.& .

" & :

1.# ;

2.# " ;

3.< .

+ :

1.& % .

2.!$ .